[Cellular immunotherapy in chronic myeloid leukemia].
Fernández
M N
MN
Servicio de Hematología y Hemoterapia, Clínica Puerta de Hierro, Madrid.
D000293:Adolescent; D000328:Adult; D000818:Animals; D014408:Biomarkers, Tumor / Q000032:analysis; D016026:Bone Marrow Transplantation / Q000009:adverse effects; D015496:CD4-Positive T-Lymphocytes / Q000276:immunology; D003586:Cytomegalovirus Infections / Q000150:complications; D017809:Fatal Outcome; D005260:Female; D016044:Fusion Proteins, bcr-abl / Q000032:analysis; D006086:Graft vs Host Disease / Q000209:etiology; D006801:Humans; D016867:Immunocompromised Host; D007155:Immunologic Factors / Q000627:therapeutic use; D016219:Immunotherapy, Adoptive / Q000009:adverse effects; D016898:Interferon-alpha / Q000627:therapeutic use; D015979:Killer Cells, Lymphokine-Activated / Q000276:immunology; D007694:Killer Cells, Natural / Q000276:immunology; D015464:Leukemia, Myelogenous, Chronic, BCR-ABL Positive / Q000150:complications / Q000175:diagnosis / Q000235:genetics / Q000628:therapy*; D017710:Lymphocyte Transfusion; D008297:Male; D009091:Mucormycosis / Q000150:complications; D009364:Neoplasm Recurrence, Local / Q000628:therapy; D012074:Remission Induction; D014019:Tissue Donors; D019172:Transplantation Conditioning
D014408:Biomarkers, Tumor; D007155:Immunologic Factors; D016898:Interferon-alpha; D016044:Fusion Proteins, bcr-abl
Inmunoterapia celular en la leucemia mieloide crónica.